Small clinical trials of inhaled A1AT in CF demonstrated some benefits including decreases in Pseudomonas aeruginosa, proinflammatory cytokines (e.g., IL-8), neutrophils and/or neutrophil markers (e.g., NE). Here, CXCL8 is linked to cystic fibrosis.